Summary
Liquidia Corp (NASDAQ:LQDA) Chief Financial Officer and Chief Operating Officer Michael Kaseta completed an insider sale on April 9, 2026, disposing of 133,789 shares of the company’s common stock for approximately $5.3 million. The shares changed hands at $40.2379 apiece, a figure modestly above the contemporaneous trading price of $38.79. On that same day Kaseta exercised options to acquire 133,789 shares at strike prices between $2.54 and $2.97, for a combined outlay of $374,032. After these transactions, Kaseta’s direct ownership totals 411,855 shares.
Transaction details
The insider sale and the near-simultaneous option exercise were recorded on April 9, 2026. The sale price of $40.2379 contrasts with the current market quote cited at $38.79. The options exercise involved the full 133,789 shares at varying low strike prices - from $2.54 to $2.97 - and the purchase cost associated with exercising those options equaled $374,032. These moves follow a period in which the stock produced a 188% return over the prior year, according to InvestingPro data.
Company performance and market reaction
Liquidia reported strong fourth-quarter results for 2025, with revenue outpacing expectations. Revenue tied to the Yutrepia launch reached $90.1 million, representing a 74% increase versus the prior quarter. Despite the revenue beat, reported earnings per share missed analysts’ estimates, a shortfall that coincided with a decline in Liquidia’s stock in pre-market trading.
Analyst responses
Several sell-side firms adjusted their views following the quarter. H.C. Wainwright raised its price target on Liquidia to $55, citing the company’s attention to profitability. BTIG lifted its target to $50, noting the strong initial returns from the Yutrepia launch. Raymond James maintained a Strong Buy rating, observing that Yutrepia’s early launch performance is comparable to Tyvaso DPI’s initial rollout. BofA Securities reiterated a Buy rating and set a $44 price target, calling out Liquidia’s competitive position in the prostacyclin treatment market.
Outlook
Management also published revenue guidance that exceeds $1 billion for 2027, signalling an expectation of substantial growth ahead. InvestingPro analysis, cited in the company’s coverage, still regards the stock as undervalued relative to its Fair Value and lists it among the platform’s most undervalued opportunities.
Key points
- Insider transaction: CFO/COO Michael Kaseta sold 133,789 shares on April 9, 2026, at $40.2379 per share and exercised 133,789 options at strikes between $2.54 and $2.97 for $374,032.
- Operational momentum: Q4 2025 revenue benefited from a strong Yutrepia launch, generating $90.1 million and a 74% quarter-over-quarter increase in related revenue.
- Analyst movement and guidance: Multiple firms raised price targets or reiterated positive ratings as management provided revenue guidance above $1 billion for 2027.
Risks and uncertainties
- Earnings volatility - Although revenue beat expectations, earnings per share fell short, a discrepancy that led to immediate negative market reaction in pre-market trading and demonstrates sensitivity in near-term stock performance.
- Insider activity interpretation - The sizable sale by an executive, even when paired with option exercises, may be viewed variably by investors and could influence short-term investor sentiment in the biotech and healthcare sectors.
- Execution against guidance - The company has set an ambitious revenue target for 2027; achieving that level depends on sustaining product launch momentum and commercial execution in the prostacyclin treatment market.
This report presents the recorded insider transactions, recent quarterly results and the prevailing analyst positions without offering investment advice. All figures cited reflect the company disclosures and third-party analysis referenced above.